Immune functions were evaluated in vitro for PBMC isolated from healthy donors and cultured with the antiviral agents, 3'-azido-3'-deoxythymidine (AZT), ribavirin, ganciclovir, 2'3'-dideoxyinosine (ddI), or acyclovir. To identify methods for assessing the effects of antiviral drugs on immune cells, the PBMC response to mitogens, Con A, or phytohemagglutinin was evaluated from measurements of [3H]thymidine and [14C]-leucine incorporation, cell growth, cellular RNA, DNA, and protein levels, and the PBMC proliferative cycle (i.e., progression from G0----G1----S----G2 + M). At clinically relevant concentrations, AZT, ribavirin, or ganciclovir diminished PBMC responsiveness to mitogen. The numbers of proliferating cells in G1, S, and G2 + M phases of the cell cycle, DNA content, and [3H]thymidine uptake were decreased in cultures treated with AZT, ribavirin, or ganciclovir. AZT or ribavirin but not ganciclovir reduced RNA and protein in the cultures and inhibited cell growth. Whereas AZT, ribavirin, or ganciclovir were antiproliferative, ddI or acyclovir had little, if any, effect on PBMC mitogenesis. The inhibitory effects of antivirals on immune cells may contribute to the immune deterioration observed in patients following prolonged use of the drugs. 
Introduction
At present there are few safe and effective drugs for treatment of viral diseases. Although antiviral activity has been demonstrated in vitro for the nucleoside analogues 3'-azido-3'-deoxythymidine (Zidovudine; Vetrovir) (AZT),' ribavirin (1-beta-D-ribofuranosyl-1,2,4-trizole-3-carboxamide; Virazole), ganciclovir (9-[1,3-dihydroxy-2-propoxymethyl] guanine; DHPG; BIOLF-62; 2NDG), and 2'3'-dideoxyinosine (ddI), neither their full therapeutic potential nor range of toxicity has been evaluated (1) (2) (3) (4) (5) (6) . By virtue of their resemblance to thymidine, adenosine, and guanosine, such nucleoside analogues are likely to have adverse effects on mammalian DNA, RNA, and/or 1. Abbreviations used in this paper: ARC, AIDS related complex; AZT, 3'-azido-3'-deoxythymidine; ddI, 2'3'-dideoxyinosine; Fl, fluorescence; HO, Hoechst 33342; PY, pyronin Y; R640, rhodamine 640.
protein synthesis, in addition to their effects on viral replication (2) . Previous studies have shown many synthetic nucleosides to be toxic on in vivo use (2) ; however, acyclovir (9-[2- hydroxyethoxymethyl]guanine) which has low in vivo and in vitro toxicity, is a notable exception (1) . Acyclovir is now widely used in renal and bone marrow transplant recipients for prophylaxis and treatment of herpes simplex virus and varicella zoster virus infections (1) .
To date, AZT is the only approved drug for treatment of HIV disease. Recent studies with ddI, however, have documented clinical improvements in HIV infected patients and even low dose therapy with ddl has resulted in statistically significant increases in CD4 cells and decreases in HIV p24 antigenemia (7) (8) (9) . Ribavirin has been used in treatment ofrespiratory syncytial virus infection (10) , influenza (1 1), and Lassa fever (12) , and ribavirin, like AZT and ddl, is currently under evaluation for its effectiveness in treatment ofHIV disease (13, 14) . Ganciclovir, which has activity against many herpes group viruses, is the first effective drug for treatment ofcytomegalovirus retinitis in patients with AIDS (15) .
The effects of nucleoside antiviral drugs on immune function have not been well defined. Although established cell lines have been cultured with the antivirals (16), the findings from such studies may not always reflect the activity ofthe drugs on freshly isolated immune response cells. Some investigators have analyzed PBMC responses in cultures treated with the nucleoside antivirals, but these studies have relied on uptake of labelled DNA/RNA precursors to assess the effects exerted by the drugs (4, (16) (17) (18) . Since these antivirals probably alter intracellular nucleotide pools (2) , the levels of incorporation for DNA/RNA precursors may not parallel the degree of DNA/ RNA synthesis in the cells, and consequently, may not be valid indicators ofcellular functions. For these reasons we have used a series of assays to evaluate, in vitro, the effects of AZT, ribavirin, ganciclovir, acyclovir, and ddl on the immune response of PBMC obtained from normal, healthy donors. PBMC responsiveness to T cell mitogens, Con A, or PHA, was measured and the effects of the antiviral drugs were assessed on the PBMC uptake of [3H]thymidine and ['4C]leucine, blastogenesis, the RNA, DNA, and protein content of activated cultures and stages of the proliferative cycle for lectin-stimulated lymphocytes. Our studies show that AZT, ribavirin, or ganciclovir were inhibitory for cultured PBMC, diminishing their responsiveness to mitogens.
Methods
Isolation of PBMC. PBMC were separated from whole, heparinized blood obtained by venipuncture from healthy volunteer donors. 30-ml portions of blood were layered over 15 ml of lymphocyte separation medium (Organon Teknika Corp., Durham, NC) and after centrifugation, cells at the interface were collected, and then washed twice in HL-I culture medium (Ventrex Laboratories, Inc., Portland, ME) supplemented with 2 mM glutamine, and 100 U/ml penicillin-streptomycin (Gibco Laboratories, Grand Island NY).
Antiviral drugs. Sources for the antivirals used in these studies were: AZT (Burroughs Wellcome Co., Research Triangle Park, NC); ribavirin (Viratek, Inc., Costa Mesa, CA); ganciclovir (Syntex Laboratories Inc., Palo Alto, CA); acyclovir (Burroughs Wellcome Co.); and ddI (Calbiochem-Behring Corp., La Jolla, CA). These agents were prepared in HL-I medium as stock solutions at 2-4 x Il0' M and serially diluted before assay.
[3H]thymidine uptake. PBMC (10) Two-color analysis ofthe cell cycle. Cultures were initiated by the transfer of 106 PBMC suspended in 1 ml of HL-I medium to 24-well plates (Costar, Data Packaging Corp., Cambridge, MA). PBMC were activated by the addition of2 ,g/ml (final) ofCon A, the antiviral drugs were added, and then the cultures were incubated at 370C in a 5% CO2 atmosphere for 3 d. Subsequently, PBMC were labelled for DNA and RNA by use of the double-staining method previously described by Shapiro (19) . Cells DNA and RNA content ofthe PBMC was analyzed by dual fluorescence flow cytometry as previously described (19, 20 [3H]thymidine incorporation for PBMC stimulated with PHA, like that for Con A, was markedly reduced for cultures incubated with AZT, ribavirin, or ganciclovir (data shown for AZT and ddI; see Fig. 1 F) . Acyclovir caused a modest impairment in labelling at the 400-MM dose and ddI had no effect on [3H]thymidine uptake in PHA or Con A-activated cultures ( AZT, ribavirin, organciclovir, but not acyclovir or ddI, were potent inhibitors ofthe PBMC proliferative response to lectin.
Upon stimulation with mitogen lymphocytes enter the proliferative cycle; quiescent cells (GO) undergo change to an activated state (GI), then progress through subsequent stages (S, G2) to mitosis (M), and in turn, the resulting daughter cells enter the cycle (24) . To measure lymphocyte proliferation and to assess the effects exerted by antiviral drugs on this immune function we determined the numbers of resting GO or cycling cells in the GI, S, G2, or M phases of the proliferative cycle in cultures of Con A-stimulated PBMC. Cell position (GO, GI, S G2 + M) in the cycle was ascertained from measurements of DNA and RNA. A double labelling technique was used to differentially stain DNA with one fluorochrome and RNA with another, and then, the DNA and RNA content for individual cells was measured by dual fluorescence flow cytometry. DNA was labelled with the DNA-specific HO dye that stains viable cells and (Figs. 2 and 3) .
Inspection of the histograms presented in Fig. 2 shows that ribavirin, like AZT, induced anomalies in the PBMC proliferative cycle. Ribavirin at 0.4AM caused an enlargement in the G2 + M compartment suggesting a defect in either the transition from G2 to M or in cell division (M) itself (Figs. 2 and 3) . When the ribavirin concentration was increased 10-fold to 4 MM there were anomalies in GI and S, and when further increased 100-fold to 40 MM, the total numbers of cycling cells measured for Gl, S, and G2 + M were markedly reduced (Figs.  2 and 3 ).
Ganciclovir at doses of 4 AM caused a detectable, albeit modest, decrease in the S and G2 + M compartments of the proliferative cycle (Fig. 2) . When the ganciclovir concentration in the cultures was increased by 10-fold to 40 AM the numbers of cells in the S and G2 + M phases of the cycle were further reduced. At 400MM ganciclovir the numbers ofcycling cells in GI, S, and G2 + M compartments diminished (Figs. 2 and 3) .
Whereas low doses (0.4 to 4 MM) of AZT, ribavirin, or ganciclovir caused abnormalities in the proliferative cycle (Figs. 2  and 3 ), equivalent concentrations ofacyclovir or ddl had little, ifany, effect on the proliferative response ofPBMC (Figs. 2 and  3 ). In fact, acyclovir or ddl were only inhibitory at high doses (. 40 MM) (Figs. 2 and 3) .
Our studies in which the proliferative cycle was analyzed by two-color staining for DNA and RNA clearly showed that incubation of lectin-stimulated PBMC with AZT, ribavirin, or ganciclovir resulted in abnormalities in the cell cycle and diminished proliferation. These findings are in agreement with our data in which PBMC proliferation was measured indirectly by [3Hlthymidine incorporation (Fig. 1) Figure 3 . PBMC progression through the cell cycle was markedly impaired by AZT, ribavirin, or ganciclovir, but not acyclovir or ddM. DNA and RNA content for PBMC incubated with Con A or Con A + antiviral drug was measured by double staining and dual fluorescence flow cytometry as described for Fig. 2 . Cell cycle position (Gl, S, and G2 + M) was then determined for the PBMC from measurements of their DNA and RNA as described for Fig. 2 (Fig. 4) . AZT, at doses as low as 4 AM, decreased the number of Con A blasts in PBMC cultures, and as the concentration of AZT was increased, blast formation was further diminished (Fig. 4 A) . Ribavirin, like AZT, inhibited blastogenesis; inhibition was detected in cultures incubated with 12 uM ribavirin, and the response was abolished in cultures incubated with 400 MM ribavirin (Fig. 4 B) . It is noteworthy that we employed cytofluorometry (i.e., measured forward and right angle light scatter) to measure the number ofblast cells in the cultures, and therefore, these measurements were obtained without aid of DNA precursors (e.g., [3Hlthymidine) or other labelling agents (e.g., HO stain for DNA). These studies eliminate the possibility that the effects measured for AZT or ribavirin on PBMC responsiveness to lectin resulted solely from artifacts caused by way ofdrug competition with nucleoside precursors or other interference with labelling procedures.
Whereas AZT and ribavirin were inhibitory, ganciclovir, acyclovir, or ddI (data shown for ganciclovir or ddI; Fig. 4 (Fig. 4, C and D) .
Ribavirin or AZT, but not ganciclovir, acyclovir, or ddI, reduced the protein content of Con A-activated PBMC. Although ribavirin was the more potent inhibitor, the incubation of Con A-activated PBMC with ribavirin or AZT diminished the protein content of the cultures (Fig. 5, A and B) . The drug concentration that resulted in a 50% reduction in protein (Ie) was 100 MM for ribavirin and 400 ,uM for AZT; the inhibitory effect titered to 4-MM doses of ribavirin or AZT (Fig. 5, A and  B) . Neither acyclovir nor ddI, on the other hand, reduced the level of protein in the lectin-activated cultures at doses < 400 MM (Fig. 5, A and B) .
The decreased levels of protein in the ribavirin-treated cultures resulted from a decline in protein synthesis since incorporation of ['4Cjleucine into the protein fraction precipitated by TCA was reduced in cultures incubated with ribavirin (Fig. 6 ).
[14C]leucine uptake was diminished at doses of 4 (Fig. 6 ).
Discussion
Recovery from viral disease is closely linked to immune function, especially T lymphocyte activity (25-27), and since synthetic nucleoside antivirals have potential toxicity, particularly on rapidly dividing cells, we have studied the effects of AZT, ribavirin, ganciclovir, ddl, and acyclovir on mitogen-stimulated immune cells. The responsiveness ofPBMC isolated from normal, healthy donors was measured for cultures incubated with or without these agents. As expected, our findings showed that acyclovir, an antiviral drug that has been extensively studied in vitro and in vivo (1, 17) , had little effect on PBMC responsiveness to mitogen (Figs. 1-3, 5) . Toxicity was observed only with high acyclovir doses; intravenous administration of acyclovir doses of 5-15 mg/kg body wt result in plasma levels of 40-92 AM (28) and our studies showed that at these concentrations the PBMC proliferative response was reduced only 10-20% (Figs. 1-3, 5 ). Interestingly, ddI had minimal toxicity even in cultures treated with high (supratherapeutic) doses of drug (Figs. 1-5) .
Whereas the PBMC response to Con A was largely unaffected by acyclovir or ddl, AZT, ribavirin, or ganciclovir diminished the lectin response (Figs. 1-6 ). The addition ofAZT, (Fig. 4) , and the RNA (Figs. 2 and 3 ) and protein content (Fig. 5) (29) Our studies show that AZT is a potent inhibitor of the PBMC response to mitogens; this drug decreased cell uptake of [3Hjthymidine, caused defects in the cell cycle, reduced growth of Con A blasts, and diminished the protein content in the cultures (Figs. 1-6 ). Mitsuya et al. (16) studied the effects of AZT on the growth of an established T helper cell line (ATH8) and they reported little difference between the viability for drug treated or nontreated cultures. It is possible that the established T cell line used for their studies was resistant to AZT toxicity since such resistance has been reported for other established cell lines (22, 30 [3H]uridine uptake into RNA for mitogen-stimulated PBMC established from one healthy donor. Inspection of these data showed that at 10MM AZT caused a detectable reduction in the level of [3H]uridine incorporated in PHA or Con A-activated cultures. Our studies, in which the RNA content ofPBMC was determined by fluorescent staining and flow cytometry, showed that AZT diminished RNA; this effect was dose dependent and the inhibition titered to AZT doses of 4 MM (see Fig. 3 ).
At present AZT is the only drug demonstrated to be effective in treatment of HIV infection; however, long term or high dose therapy with AZT has resulted in severe toxicity, particularly anemia and neutropenia (31) . Peak plasma levels attained for high dose AZT range between 6 and 10 MAM (32). We find that AZT caused abnormalities in the proliferative cycle oflectin-stimulated PBMC at concentrations as low as 0.4 AM (Figs.   2 and 3) , and our studies, as well as those ofMitsuya et al. (16) , have indicated that therapeutic levels ofAZT inhibit RNA synthesis in PBMC cultures. Taken together, these findings suggest that AZT may adversely affect immune functions dependent on proliferation or RNA and protein synthesis (e.g., elaboration of lymphokines). In AIDS, where viral replication occurs in immune response cells, it is possible that the toxicity resulting from such an antiviral may be enhanced. Since patients with HIV disease have cellular immune deficiencies at the outset of treatment, any agent that further depresses the immune response may, particularly over the long term, provide little value to the patient.
Recent studies (33, 34) have shown that in patients with AIDS or the AIDS related complex (ARC) low doses (300 mg) of AZT cause less toxicity than higher doses (600-1,500 mg) but provide the same clinical and virologic effects as the higher doses. Fischl et al. (33) reported that in the AIDS patients treated with AZT the numbers of CD4 cells are transiently increased but subsequently diminished after 8 wk of therapy. The studies of Collier et al. (34) have shown that in patients with ARC the greatest improvement in mean CD4 lymphocyte counts was in patients treated with low doses of AZT. It is noteworthy that our studies point out the dose-dependent effects ofAZT on lymphocytes, and therefore our findings would have predicted less toxicity with the low dose of AZT as has been recently demonstrated in clinical trials (33, 34) . The methods used-in our studies may be applicable to the study of other new antiviral compounds, and "prescreening" tests such as those we have used here could be performed before the clinical use of systemic antiviral agents.
We find that ribavirin, like AZT, diminished PBMC responsiveness to lectin. Our studies, as well as those of others (35) (Fig. 6) , diminished the capacity of lectin-stimulated PBMC to progress through the cell cycle (Figs. 2 and 3) , and reduced blastogenesis (Fig. 4) . Defects in the cell cycle resulted when PBMC were incubated with ribavirin doses of0. 4 (Figs. 1-6 ). We have employed highly sensitive methods to assess the effects ofribavirin on the PBMC response to lectin and differences between the methodologies used by Drach et al. (35) and us most likely account for the disparities between these studies.
In clinical trials where patients with AIDS or ARC have been treated with oral ribavirin doses of 600-800 mg/d and in which steady-state serum levels were maintained between 8 and 10 uM the p24 antigen was decreased and the CD4 cell number and lymphocyte proliferative response to lectin were enhanced (13, 36) . With higher dose regimens of 1,200 to 1,600 mg/d of ribavirin the steady-state serum levels were greater than 13 ,gM and the CD4 cell number, lymphoproliferation, or p24 antigen status showed no improvement (36) . In fact, Roberts et al. (37) have reported that the lymphocyte counts decreased in the patient group treated with 1,200 to 1,600 mg/d of ribavirin suggesting possible lymphocyte toxicity. Interestingly, our studies show that ribavirin inhibition of the PBMC response to lectin was dose dependent and that responsiveness declined precipitously in cultures incubated with ribavirin concentrations > 12 MM. It is possible that the treatment failure observed with higher ribavirin doses is linked to the toxicity of this agent on immune functions and that lower doses of the drug may avoid this toxicity.
It is noteworthy that our studies show AZT but not ddI to be a potent inhibitor of PBMC mitogenesis. Similar findings have been reported for bone marrow cell cultures (38) ; whereas low concentrations of AZT (i.e., 1.0 MM) have inhibited myelopoiesis or erythropoiesis, ddI has been shown to have little effect on the growth of bone marrow progenitor cells (38) (39) (40) . Mitsuya and Broder (4) reported that similar concentrations of ddI had no effect on the viability ofan established T helper cell line. The major adverse effects noted in patients treated with ddI have been dose-dependent peripheral neuropathy, and in some patients, pancreatitis (9, 41) . Early results from clinical studies show that p24 antigenemia has decreased and numbers of CD4 lymphocytes have increased in patients receiving ddI (9, 41) . Possibly, ddI may prove safe and beneficial as an antiretroviral drug by avoiding lymphocyte toxicity. Further clinical study will determine the efficacy for ddI in HIV disease. Further in vitro studies of antiviral agents before their clinical use should allow us to make predictions about the consequences of these agents upon the host immune system. Funding for this work was provided by grants from the National Institutes of Health (CA-34979, AI-29173, and AI-27659), United States
